MMP-2产品信息
英文名称:Matrix metalloproteinase-2
中文名称:基质金属蛋白酶-2
靶点别称:MMP2,CLG4,CLG4A,MMP-II,MONA,TBE-1
物种:Human
属性:Protein
标记:Unconjugated
内毒素(Endotoxin)
Less than 1.0 EU per μg by the LAL method.
纯度(Purity)
>85% as determined by SDS-PAGE.
制剂(Formulation)
Supplied as 0.2 μm filtered solution in 50 mM Tris, 150 mM NaCl, 20% glycerol, pH7.5 with trehalose as protectant.
Contact us for customized product form or formulation.
运输(Shipping)
This product is supplied and shipped with dry ice, please inquire the shipping cost.
存储(Storage)
Please avoid repeated freeze-thaw cycles.
This product is stable after storage at:
The product MUST be stored at -70°C or lower upon receipt;
-70°C for 6 months under sterile conditions.
![1.jpg 1.jpg](/SupplyImg/2024-04-30/6385007281281437415731368.jpg)
MMP-2分子背景
Matrix metalloproteinase-2 (MMP-2) is also known as 72 kDa type IV collagenase, 72 kDa gelatinase, Gelatinase A and CLG4A, which belongs to the peptidase M10A family. MMP-2 / CLG4A contains 3 fibronectin type-II domains and 4 hemopexin-like domains. MMP-2 is produced by normal skin fibroblasts. MMP-2 cleaves the collagen-like sequence Pro-Gln-Gly-|-Ile-Ala-Gly-Gln. MMP2 involved in diverse functions such as remodeling of the vasculature, angiogenesis, tissue repair, tumor invasion, inflammation, and atherosclerotic plaque rupture. As well as degrading extracellular matrix proteins, can also act on several nonmatrix proteins such as big endothelial 1 and beta-type CGRP promoting vasoconstriction. Also cleaves KISS at a Gly-|-Leu bond. Appears to have a role in myocardial cell death pathways. Contributes to myocardial oxidative stress by regulating the activity of GSK3beta. Cleaves GSK3beta in vitro. PEX, the C-terminal non-catalytic fragment of MMP2, posseses anti-angiogenic and anti-tumor properties and inhibits cell migration and cell adhesion to FGF2 and vitronectin.
![通用.jpg 通用.jpg](/SupplyImg/2024-04-30/6385007281963661078284358.jpg)
关键字: MMP-2;MMP-2蛋白;基质金属蛋白酶2;ACRO;百普赛斯;
百普赛斯集团ACROBiosystems Group(股票代码:301080)是成立于2010年的跨国生物科技公司,是为全球生物医药、健康产业领域提供关键生物试剂产品及解决方案的行业平台型基石企业。2021年在创业板上市。百普赛斯集团业务遍布全球,横跨亚洲、北美洲、欧洲,在中国、美国、瑞士等12个城市设有办公室、研发中心及生产基地。目前累计服务客户超6000家,与全球Top 20医药企业均建立了长期、稳定的合作伙伴关系。集团旗下拥有品牌ACROBiosystems百普赛斯、bioSeedin柏思荟、Condense Capital垦拓资本和ACRODiagnostics百斯医学等。